Abstract
A series of 30 tripeptides were synthesized and tested as novel 5-HT4 receptor ligands. Receptor binding assays showed that a subset of compounds had reasonable potency relative to the agonists serotonin and 5-methoxytryptamine. Structure-activity analyses and molecular docking have highlighted avenues for further synthetic work.
Keywords: Serotonin, 5-HT, 5-HT4, tripeptide, molecular docking, radioligand binding
Protein & Peptide Letters
Title: The Use of Tripeptides for Lead Discovery of 5-HT4 Receptor Ligands
Volume: 16 Issue: 7
Author(s): A. Hanna-Elias, P. E. Thompson, D. T. Manallack, H. R. Irving, I. M. Coupar, I. Berque-Bestel and M. N. Iskander
Affiliation:
Keywords: Serotonin, 5-HT, 5-HT4, tripeptide, molecular docking, radioligand binding
Abstract: A series of 30 tripeptides were synthesized and tested as novel 5-HT4 receptor ligands. Receptor binding assays showed that a subset of compounds had reasonable potency relative to the agonists serotonin and 5-methoxytryptamine. Structure-activity analyses and molecular docking have highlighted avenues for further synthetic work.
Export Options
About this article
Cite this article as:
Hanna-Elias A., Thompson E. P., Manallack T. D., Irving R. H., Coupar M. I., Berque-Bestel I. and Iskander N. M., The Use of Tripeptides for Lead Discovery of 5-HT4 Receptor Ligands, Protein & Peptide Letters 2009; 16 (7) . https://dx.doi.org/10.2174/092986609788681805
DOI https://dx.doi.org/10.2174/092986609788681805 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Cell Sheet-Based Myocardial Tissue Engineering: New Hope for Damaged Heart Rescue
Current Pharmaceutical Design Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
Current Medicinal Chemistry Soy Isoflavones and Cardiovascular Health: An Update
Current Nutrition & Food Science Clinical Impacts in Cardiovascular Molecular Imaging: the Example of Cardiac Sympathetic Imaging in Heart Failure
Current Medical Imaging Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Endocrine Therapies and QTc Prolongation
Current Drug Safety Molecular Pharmacology of Non-L-type Calcium Channels
Current Pharmaceutical Design Prevention of Renal Complications Induced by Non- Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Cardiac Effects of HDL and Its Components on Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Synthesis of 2-(4-substitutedbenzylpiperazin-1-yl)-N-(2-oxo-2,3-dihydrobenzooxazol- 6-yl)acetamides as Inotropic Agents
Medicinal Chemistry Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Connexin43 and Myocardial Ischemia-Reperfusion Injury
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress-Induced Ischemic Heart Disease: Protection by Antioxidants
Current Medicinal Chemistry The Inflammation Paradigm and Coronary Artery Disease: What Celsus, Virchow and Gene Knock Outs Have Taught Us
Cardiovascular & Hematological Disorders-Drug Targets The Role of Quinidine in the Pharmacological Therapy of Ventricular Arrhythmias ‘Quinidine'
Mini-Reviews in Medicinal Chemistry Skeletal Muscle Derived Stem Cells for Myocardial Repair
Recent Patents on Cardiovascular Drug Discovery Will this be the End of the Anticoagulation Clinic for Patients with Atrial Fibrillation?
Current Drug Targets - Cardiovascular & Hematological Disorders Preclinical Testing of Drug-Induced Proarrhythmia: Value of Transgenic Models
Cardiovascular & Hematological Agents in Medicinal Chemistry